Systematic review shows favorable prognosis and immunotherapy potential in POLE-mutated endometrial cancer, indicating future treatment opportunities.
POLE mutations in endometrial cancer are associated with a favorable prognosis and show promising potential for immunotherapy. Molecular subtyping that incorporates POLE mutation status should be considered standard practice for risk stratification and treatment planning.
No takes yet. Share an insight, caveat, or question.
Adella et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: